668 related articles for article (PubMed ID: 25911625)
1. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and antiproliferative activity evaluation of m-(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro.
Wang XM; Xu J; Xin MH; Lu SM; Zhang SQ
Bioorg Med Chem Lett; 2015 Apr; 25(8):1730-1735. PubMed ID: 25765909
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere.
Shao T; Wang J; Chen JG; Wang XM; Li H; Li YP; Li Y; Yang GD; Mei QB; Zhang SQ
Eur J Med Chem; 2014 Mar; 75():96-105. PubMed ID: 24530495
[TBL] [Abstract][Full Text] [Related]
4. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
5. Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents.
Li H; Wang XM; Wang J; Shao T; Li YP; Mei QB; Lu SM; Zhang SQ
Bioorg Med Chem; 2014 Jul; 22(14):3739-48. PubMed ID: 24878359
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
Li S; Wang X; He Y; Zhao M; Chen Y; Xu J; Feng M; Chang J; Ning H; Qi C
Eur J Med Chem; 2013 Sep; 67():293-301. PubMed ID: 23871909
[TBL] [Abstract][Full Text] [Related]
8. Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.
Mahal K; Resch M; Ficner R; Schobert R; Biersack B; Mueller T
ChemMedChem; 2014 Apr; 9(4):847-54. PubMed ID: 24678059
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anticancer activities of 4-(4-substituted piperazin)-5,6,7-trialkoxy quinazoline derivatives.
Zhang Y; Huang YJ; Xiang HM; Wang PY; Hu DY; Xue W; Song BA; Yang S
Eur J Med Chem; 2014 May; 78():23-34. PubMed ID: 24675177
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, in vitro and in vivo evaluation of novel substituted N-(4-(2-(4-benzylpiperazin-1-yl)ethoxy)phenyl)-N-methyl-quinazolin-4-amines as potent antitumor agents.
Cao D; Wang X; Lei L; Ma L; Wang F; Wang C; Tang M; Xiang W; Wang T; Li H; Chen L
Bioorg Med Chem Lett; 2016 Apr; 26(8):1931-5. PubMed ID: 26979159
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.
Wang XM; Xu J; Li YP; Li H; Jiang CS; Yang GD; Lu SM; Zhang SQ
Eur J Med Chem; 2013 Sep; 67():243-51. PubMed ID: 23871904
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-arylaminoquinazolines bearing
Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
[TBL] [Abstract][Full Text] [Related]
14. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
15. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel 6-chloro-quinazolin derivatives as potential antitumor agents.
Luo H; Yang S; Cai Y; Peng Z; Liu T
Eur J Med Chem; 2014 Sep; 84():746-52. PubMed ID: 25064351
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents.
Alanazi AM; Abdel-Aziz AA; Al-Suwaidan IA; Abdel-Hamide SG; Shawer TZ; El-Azab AS
Eur J Med Chem; 2014 May; 79():446-54. PubMed ID: 24763265
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antiproliferative activity of 4-substituted-piperazine-1-carbodithioate derivatives of 2,4-diaminoquinazoline.
Cao SL; Han Y; Yuan CZ; Wang Y; Xiahou ZK; Liao J; Gao RT; Mao BB; Zhao BL; Li ZF; Xu X
Eur J Med Chem; 2013 Jun; 64():401-9. PubMed ID: 23665106
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
